Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study of Egyptian patients on hepatitis C treatment, 34% experienced skin-related side effects from sofosbuvir and daclatasvir, such as itching and hyperpigmentation, but most reactions were mild and reversible without needing to stop therapy.

This case report highlights that a patient developed alopecia areata following treatment with sofosbuvir and ribavirin for chronic hepatitis C.

This study found that betulinic acid inhibits hepatitis C virus replication by suppressing the NF-κB- and ERK1/2-mediated COX-2 pathway, suggesting its potential as a therapeutic supplement.

This review covers the potential of repurposing existing drugs for treating COVID-19 and updates on virus- and host-targeting drug candidates, reporting no new experimental results.

Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.

PRP treatment for hair loss shows promise, with 58% of patients satisfied and most noticing improvement within 6 months.

The moisturizer with phytol improved skin texture and reduced fine wrinkles better than the moisturizer without it.

PLAU and SerpinB2 affect cell death differently in various forms of leprosy and could be targets for new treatments.

A woman with a skin disorder was found to have hepatitis C, which may be linked, and was safely treated with methotrexate.

This review discusses the molecular mechanisms by which oncogenic viruses contribute to cancer development through manipulation of host cellular functions and highlights the need for further research into virus-associated cancers, reporting no new results.

This study reports that synthetic carbohydrate receptors effectively inhibit Zika virus infection in cell cultures by blocking early stages of viral entry.

In this study, researchers examined chronic hepatitis B patients and found that those undergoing interferon therapy reported higher quality of life than those on non-antiviral or nucleoside/nucleotide analogue treatments, despite potential side effects.

This study reviewed 16 notable drug repurposing patent applications from 2025, highlighting potential new uses such as guanfacine for autonomic dysfunction and disulfiram for subarachnoid hemorrhage survival, though many disclosures lack peer-reviewed studies and no patents are granted.

This study investigated the relationship between lichen planus and dyslipidemia but did not report any clinical findings.

This abstract discusses the dermatological symptoms associated with hepatitis C virus infections but reports no new research findings.

This study demonstrated that a computational screening process can identify existing drugs and natural compounds with potential anti-COVID-19 activity, highlighting some candidates for further experimental validation.

This case study reported an improvement in lower limb edema for a patient with type 2 diabetes mellitus after starting dulaglutide treatment, suggesting a potential role of the drug in sodium retention disorders.

This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.

This study found that in lamivudine-resistant hepatitis B patients, tenofovir significantly reduced HBV DNA levels faster and more consistently than adefovir, reaching undetectable levels in all treated patients by 44 weeks.

This review discusses recent advances in monophosphate prodrug strategies for HCV drug discovery, aiming to enhance oral absorption and stability, and reports no new clinical results.

In this study, combining deferasirox with sorafenib significantly reduced liver fibrosis and preneoplastic lesions in rats while also lessening adverse effects compared to sorafenib alone.

This study identified five FDA-approved drugs, including cepharantine and clofazimine, as potential COVID-19 therapies through in silico and in vitro screening targeting viral entry mechanisms.

This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.

This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.

This study identified several compounds, including Pictilisib and Nimorazole, that may have higher binding affinity for SARS-CoV-2 main protease than existing inhibitors, potentially offering new treatment alternatives for Covid-19.

This study found that SARS-CoV-2 hijacks the host factor IGF2BP1 to stabilize its RNA and enhance translation, and identified Cepharanthine and Trifluoperazine as potential treatments against the virus.

This molecular docking study reported that danoprevir, remdesivir, and saridegib exhibit stronger binding affinities to the main protease of SARS-CoV-2 than the control, suggesting their potential as inhibitors of the virus's replication process.

During treatment with interferon/ribavirin for hepatitis C, this study observed significant and lasting improvement in a patient's psoriasis without additional psoriasis-specific therapies.

This study identifies five compounds, including gemcitabine and methylene blue, that inhibit SADS-CoV and suggests their potential for developing antiviral drugs against future outbreaks.